儿童质子泵抑制剂使用与哮喘风险的关联
中位随访3.0年发现,启动PPI者哮喘发生率更高(21.8 vs 14.0每1000人年),风险比1.57(95%CI 1.49-1.64),所有年龄段风险均升高,婴幼儿最高。结论提示儿童启动PPI与非使用相比与哮喘风险增加相关,应仅在明确指征时处方。
要点
- 儿童启动PPI者哮喘发生率为21.8每1000人年,未启动者为14.0每1000人年。
- 总体风险比1.57(95%CI 1.49-1.64),所有年龄段风险均显著升高。
- 婴幼儿风险最高:<6月龄HR 1.83,6月龄至<2岁HR 1.91。
核心结论
- 儿童启动PPI使用与非使用相比,与哮喘风险增加相关。
- PPI应仅在明确指征时处方给儿童,并权衡潜在获益与潜在危害。
研究设计与样本
- 瑞典全国登记数据队列研究,收集2007年1月1日至2016年12月31日数据。
- 中位随访3.0年(四分位距2.1-3.0年),采用Cox比例风险回归估计风险比。
主要发现
- PPI启动者哮喘发生率为21.8事件每1000人年,未启动者为14.0事件每1000人年。
- 总体风险比1.57(95%CI 1.49-1.64)。
- 个体PPI的HR:埃索美拉唑1.64(95%CI 1.50-1.79),兰索拉唑1.49(95%CI 1.25-1.78),奥美拉唑1.43(95%CI 1.35-1.51),泮托拉唑2.33(95%CI 1.30-4.18)。
- 启动PPI后不同时间窗的HR:0-90天1.62(95%CI 1.42-1.85),91-180天1.73(95%CI 1.52-1.98),181天至随访结束1.53(95%CI 1.45-1.62)。
关键数值与推荐
- 总体匹配队列中63.0%为女孩,平均年龄12.9岁(标准差4.8岁)。
- 高维倾向评分匹配敏感性分析HR为1.48(95%CI 1.41-1.55)。
临床怎么用
- 对儿童处方PPI前应确认明确指征,并评估潜在获益与潜在危害。
- 对启动PPI的儿童,尤其婴幼儿,应关注后续哮喘发生的可能性。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The use of proton pump inhibitors (PPIs) in children has increased substantially in recent years, concurrently with emerging concerns that these drugs may increase the risk of asthma. Whether PPI use in the broad pediatric population is associated with increased risk of asthma is not known. OBJECTIVE: To investigate the association between PPI use and risk of asthma in children. DESIGN, SETTING, AND PARTICIPANTS: This nationwide cohort study collected registry data in Sweden from January 1, 2007, to December 31, 2016. Children and adolescents 17 years or younger were matched by age and propensity score into 80 870 pairs of those who initiated PPI use and those who did not. Data were analyzed from February 1 to September 1, 2020. EXPOSURES: Initiation of PPI use. MAIN OUTCOMES AND MEASURES: The primary analysis examined the risk of incident asthma with a median follow-up to 3.0 (interquartile range, 2.1-3.0) years. Cox proportional hazards regression was used to estimate hazard ratios (HRs). RESULTS: Among the 80 870 pairs (63.0% girls; mean [SD] age, 12.9 [4.8] years), those who initiated PPI use had a higher incidence rate of asthma (21.8 events per 1000 person-years) compared with noninitiators (14.0 events per 1000 person-years), with an HR of 1.57 (95% CI, 1.49-1.64). The risk of asthma was significantly increased across all age groups and was highest for infants and toddlers with an HR of 1.83 (95% CI, 1.65-2.03) in the group younger than 6 months and 1.91 (95% CI, 1.65-2.22) in the group 6 months to younger than 2 years (P < .001 for interaction). The HRs for individual PPIs were 1.64 (95% CI, 1.50-1.79) for esomeprazole, 1.49 (95% CI, 1.25-1.78) for lansoprazole, 1.43 (95% CI, 1.35-1.51) for omeprazole, and 2.33 (95% CI, 1.30-4.18) for pantoprazole. In analyses of the timing of asthma onset after PPI initiation, the HRs were 1.62 (95% CI, 1.42-1.85) for 0 to 90 days, 1.73 (95% CI, 1.52-1.98) for 91 to 180 days, and 1.53 (95% CI, 1.45-1.62) for 181 days to end of follow-up. The association was consistent through all sensitivity analyses, including high-dimensional propensity score matching (HR, 1.48; 95% CI, 1.41-1.55). CONCLUSIONS AND RELEVANCE: In this cohort study, initiation of PPI use compared with nonuse was associated with an increased risk of asthma in children. Proton pump inhibitors should be prescribed to children only when clearly indicated, weighing the potential benefit against potential harm.
引用
- Wang YH, Wintzell V, Ludvigsson JF, et al. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children. JAMA Pediatr. 2021. PMID: 33555324. doi:10.1001/jamapediatrics.2020.5710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。